Tofacitinib

ATC Code L04AF01

Tofacitinib

Definition

An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.

Also known as 3-((3R,4R)-4-Methyl-3-(Methyl(7H-Pyrrolo(2,3-D)Pyrimidin-4-yl)Amino)Piperidin-1-yl)-3-Oxopropanenitrile, CP 690550, CP-690,550 Free Base, CP-690550, CP690550, JAK inhibitors: tofacitinib, Tasocitinib, TOFACITINIB — per NCIT

Also identified as

Indications

Disease Relation Source
Rheumatoid arthritis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Bone element may treat a disease of this organ DERIVED · CC BY 4.0
Musculoskeletal system may treat a disease of this organ DERIVED · CC BY 4.0
Skeletal joint may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.